BioGaia AB
Company Profile
Business description
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
Contact
Kungsbroplan 3A
StockholmSE-112 27
SWET: +46 855529300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
243
Stocks News & Analysis
stocks
Australia’s oldest REIT undervalued
stocks
Stop asking if there’s a stock market bubble. Ask this instead.
stocks
Are negative AI narratives holding this ASX share back?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,931.40 | 71.60 | -0.80% |
| CAC 40 | 8,327.83 | 76.16 | -0.91% |
| DAX 40 | 24,988.08 | 7.73 | -0.03% |
| Dow JONES (US) | 52,348.29 | 29.09 | 0.06% |
| FTSE 100 | 10,454.48 | 42.64 | -0.41% |
| HKSE | 22,881.02 | 145.66 | -0.63% |
| NASDAQ | 26,118.76 | 94.96 | -0.36% |
| Nikkei 225 | 70,474.96 | 412.64 | 0.59% |
| NZX 50 Index | 13,610.50 | 11.16 | -0.08% |
| S&P 500 | 7,488.45 | 10.91 | -0.15% |
| S&P/ASX 200 | 8,722.90 | 71.70 | -0.82% |
| SSE Composite Index | 4,094.40 | 20.50 | 0.50% |